Treatment options for pregnant women with epilepsy

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 11, 2008, Pages 1859-1868

  Vajda, F J E ^a,b,c,d  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

^d Australian Pregnancy Register for Women with Epilepsy   (Australia)

Author keywords

Anticipation of pregnancy; Cognitive effects; Epilepsy syndrome; Folate; Monotherapy; Pharmacotherapy; Seizures; Teratogenicity; Traditional and second generation antiepileptic drugs; Vitamin supplements

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; TIAGABINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ABNORMAL LABORATORY RESULT; AGITATION; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE DEVELOPMENT; DEPRESSION; DISEASE CONTROL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EPILEPSY; FETUS DEVELOPMENT; FETUS MALFORMATION; FETUS MONITORING; FETUS RISK; FOCAL EPILEPSY; GENERALIZED EPILEPSY; GROWTH RETARDATION; HIGH RISK PREGNANCY; HUMAN; HYPONATREMIA; IMMUNE DYSREGULATION; LOW DRUG DOSE; MALAISE; MATERNAL CARE; MENTAL DEFICIENCY; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; PREGNANCY; PREGNANCY REGISTRY; PRENATAL DRUG EXPOSURE; RASH; REGISTRATION; REVIEW; SEIZURE; SIDE EFFECT; TERATOGENICITY; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION;

ABNORMALITIES, DRUG-INDUCED; ANTICONVULSANTS; CHILD; COGNITION; EPILEPSY; FEMALE; FETUS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; REGISTRIES;

EID: 49649086942     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.11.1859     Document Type: Review

References (75)

1. Glauser T, Ben Menachem E, Bourgois B, et al. ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47(7):1094-267
2. Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005;46(Suppl 4):31-7
3. Pennell PB. Using current evidence in selecting antiepileptic drugs for use during pregnancy. Epilepsy Curr 2005;5(2):45-51
4. Tomson T, Battino D, French J, et al. Antiepileptic drug exposure and major congenital malformations: the role of the pregnancy registries. Epilepsy Behav 2007;11(3):277-82
5. Beghi E, Annegers J; for the Collaborative Group of Pregnancy Registries in Epilepsy. Pregnancy registries in epilepsy. Epilepsia 2001;42(11):1422-5
6. Pack AM. Therapy insight: clinical management of pregnant women with epilepsy. Nat Clin Pract Neurol 2006;2(4):190
7. Cunnington M, Ferber S, Quartey G. International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2006;48(6)1207-10
8. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-4
9. Vajda FJ, O'Brien T, Hitchcock A, et al. The internal control group in a register of antiepileptic drug use in pregnancy. J Clin Neurosci 2007;
10. The EURAP Study Group. Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry. Neurology 2006;66:354-60
11. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83
12. Vajda FJE, Lander CM, O'Brien TJ, et al. Foetal malformations and seizure control: 52 months data reported from the Australian Register of Pregnancies. Eur J Neurol 2006;13:645-54
13. Tomson T, Perucca E, Battino D. Navigating toward fetal and maternal health: the challenge of treating epilepsy in pregnancy. Epilepsia 2004;45:1171-5
14. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001;42:750-3
15. Kaaja E, Kaaja R, Hiilesmaa. Major malformations in the offspring of women with epilepsy. Neurology 2003;60:575-9
16. Morrow JL, Craig JJ. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register J Neurol Neurosurg Psychiatry 2006;71:193-8
17. Samren E, van Duijn C, Christiaens G, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46
18. Holmes L, Harvey E, Coull B, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-8
19. Holmes LB, Wyszynski DF, Lieberman E. The AED (Antiepileptic Drug) Pregnancy Registry. Arch Neurol 2004;61(5):673-8
20. Wyszinski DF, Nambisian M, Surve T, et al. Antiepileptic Drug Pregnancy Register. Increased rate of major fetal malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5
21. Meadow S. Anticonvulsant drugs and congenital abnormalities. Lancet 1968;ii:1296
22. Lindhout D, Omtzigt JG, Cornel MC. Spectrum of neural tube defect in 34 infants prenatally exposed to antiepileptic drugs. Neurology 1992;42(Suppl 5);S111-8
23. Kaneko S, Battino D, Andermann E, et al, Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58
24. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study Epilepsia 1999;40:1231-36
25. Dolk H, McElhatton P. Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medication. J Med Genet 2002;39:243-4
26. Kaplan PW. Reproductive health effects and teratogenicity of antiepileptic drugs. Neurology 2004;63(Suppl 4):S13-23
27. Katz J, Pacia S, Devinsky O. Current management of epilepsy and pregnancy: fetal outcome, congenital malformations, and developmental delay. Epilepsy Behav 2001;2:119-23
28. Malm H, Kajantie E, Kivirikko S, et al. Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility. Neurology 2002;59(4):630-3
29. Wide K, Windbladh B, Kallen B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr Scand 2004;93:174-6
30. Eadie MJ, Vajda F. Should valproate be taken during pregnancy? Ther Clin Risk Manage 2005;1:21-6
31. Vajda FJE, Eadie MJ. Maternal valproate dosage and foetal malformations. Acta Neurol Scand 2005;112:137-43
32. Perucca E. Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol 2005;4(11):781-6
33. Vajda FJ, Hitchcock A, Graham J, et al. Seizure control in antiepileptic treated pregnancy. Epilepsia 2008;49(1):172-6
34. Panayiotopoulos CP. The epilepsies. Seizures, syndromes and management. Oxford: Bladon Medical Publishing; 2005. P. 76-80
35. Berry RJ, Li Z, Erickson JD, et al. Prevention of neural-tube defects with folic acid in China. New Eng J Med 1999;341:1485-90
36. MRC Vitamin Study Research Group (1991). Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131
37. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptual vitamin supplementation. N Engl J Med 1992;327:1832-5
38. Craig J, Morrison P, Morrow J, et al. Failure of periconceptual folic acid to prevent a neural tube defect in the offspring of a mother taking sodium valproate. Seizure 1999;8:253-4
39. Rosenberg IH. Folic acid and neural-tube defects: time for action? N Engl J Med 1992;327(26):1875-7
40. Yerby MS. Clinical care of pregnant women with epilepsy: neural tube defects and folic acid supplementation. Epilepsia 2003;44(Suppl 3):33-40. Erratum: 2003;44:1465
41. Yerby MS. Management issues for women with epilepsy. Neural tube defects and folic acid supplementation. Neurology 2003;61(6 Suppl 2):S23-6
42. Rothenberg SB, da Costa M, Sequeira MS, et al. Production of antibodies to folate receptors in women with a pregnancy complicated by a neural tube defect. N Eng J Med 350;2:134-42
43. Botto D, Lisi A, et al. 2005 International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? BMJ 2007;334:433-4
44. Lumley J, Watson L, Watson M, Bower C. Periconceptional supplementation with folate and/or multivitamins for preventing neural tube defects. Cochrane Database Syst Rev 2001;(3):CD001056
45. Vajda FJE, Hitchcock A, Graham J, et al. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007;47:468-74
46. Liporace J, Kao A, D'Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004;5:102-5
47. Ben Menachem E, Scheepers B, Stodieck S. Epilepsy: from consensus to daily practice. Acta Neurol Scand 2003;108(Suppl 180):5-15
48. Tomson T, Hiilesmaa V. Epilepsy in pregnancy. BMJ 2007;(335):769-73
49. Pennell P. Antiepileptic drug pharmacokinetics during pregnancy and lactation. Neurology 2003;61:S35-42
50. Brodie MJ, Dichter MA. New antiepileptic drugs. N Engl J Med 1996;334(24):1583-90
51. Vajda FJ, O'Brien TJ, Hitchcock A, et al. Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy. J Clin Neurosci 2004;11(8):854-8
52. Marson, A, Al-Kharusi, A, Alwaidh, A., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial. Lancet 2007;(369):1000-15
53. Vajda FJE. Pharmacotherapy of epilepsy. J Clin Neurosci 2007;14(9):813-23
54. Tomson T, Battino D. Pharmacokinetcs and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007;46:209-19
55. Vajda FJE. Monitoring antiepileptic therapy with serum level measurements. Med J Aust 2007;187:582-4
56. Tomson T, Palm R, Kallen K, et al. Pharmacokinetics of levetiracetam during pregnancy, deliver, in the neonatal period, and lactation. Nat Clin Pract Neurol 2007;3(10):538-9
57. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res 2001;47(1-2):151-4
58. Vajda F, Solinas C, Graham J, et al. The case for lamotrigine monitoring in pregnancy. J Clin Neurosci 2006;13:103-4
59. Hyumni C, Morrell MJ. Review of LTG and its clinical applications in epilepsy. Expert Opin Pharmacother 2003;(2):243-51
60. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85(2):77-85
61. Mula M, Trimble MR, Yuen A, et al. Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-6
62. Weintraub D, Buchsbaum R, Spencer HT, et al. Psychiatric side effects of the newer antiepileptic drugs: results of the Columbia antiepileptic drug database; Program and abstracts of the 56th Annual Meeting of the American Academy of Neurology; 24 April - 1 May, San Francisco, California [Abstract P04.085]
63. Eriksson K. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long term cognitive development. Epilepsy Res 2005;65:189-200
64. Gaily E, Kantola-Sorsa E, Hillesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32
65. Vinten J, Adab N, Kini U, et al. for the Liverpool and Manchester Neurodevelopment Study Group. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:949-54
66. Duchowny M. Neurobehavioral teratogenicity in antiepileptic drugs. The new Pandora's box. Editorial Neurol 2004;62:89
67. Meador K. Valproate poses risk to unborn child. Epilepsy Curr 2005;5(3)116-7
68. Thomas SV, Sukumaran S, Lukose N, et al. Intellectual function and language functions in children of mothers with epilepsy. Epilepsia 2007;48:2234-40
69. Vajda FJE, O'Brien TJ, Graham J, et al. Pregnancies in women with epilepsy. J R Coll Physicians Edinb 2006;36:201-7
70. Eadie MJ. Antiepileptic drugs as human teratogens. Expert Opin Drug Saf 2008;7(2):195-209
71. Kondo T, Kaneko S, Amano Y, Egawa I. Preliminary report on teratogenic effects of zonisamide in the offspring of treated women with epilepsy Epilepsia 1996;37:1242-4
72. Artama M, Auvinen A, Raudaskoski T, et al. Antiepileptic drug use of women with epilepsy and congenital malformations in the offspring. Neurology 2005;64:1874-8
73. Mieschenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004;5:163-7
74. Long L. Levetiracetam monotherapy during pregnancy: a case series. Epilepsy Behav 2003;4:447-8
75. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2000;67:1876-9